베타
임상 레이더 AI
임상시험 NCT07493746은(는) 발달성 고관절 이형성증에 대해 대상자모집전 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

Hip Arthroscopy Versus Conservative Treatment for Borderline Hip Dysplasia 248 운동

대상자모집전
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07493746은(는) 발달성 고관절 이형성증에 대해 알아보는 중재연구입니다. 현재 상태는 대상자모집전이며, 2026년 6월 1일부터 참여 신청이 가능합니다. 248명의 참여자를 모집할 예정입니다. ChunBao Li이(가) 진행하는 이 연구는 2029년 6월 30일까지 진행될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 25일에 갱신되었습니다.
간단한 개요
The goal of this clinical trial is to compare the efficacy of hip arthroscopy versus individualized conservative treatment in patients with borderline developmental dysplasia of the hip (BDDH), defined by a lateral center-edge angle (LCEA) of 18-25°. The main question it aims to answer is: which treatment approach, surgical or conservative, provides superior pain relief, functional recovery, and quality of life impro...더 보기
상세한 설명
This multicenter, prospective, randomized controlled trial aims to compare the efficacy of hip arthroscopy versus individualized conservative treatment in patients with borderline developmental dysplasia of the hip (BDDH). BDDH, defined by a lateral center-edge angle (LCEA) of 18-25°, represents a distinct condition between normal hips and developmental dysplasia of the hip, and its optimal management remains controv...더 보기
공식 제목

Arthroscopic Hip Surgery Versus Individualized Conservative Treatment for Borderline Hip Dysplasia: A Multicenter Prospective Randomized Controlled Trial

질환명
발달성 고관절 이형성증
기타 연구 식별자
  • 2026KY001-HS001
NCT 번호
실제 연구 시작일
2026-06-01
최신 업데이트 게시
2026-03-25
예상 연구 완료일
2029-06-30
계획된 등록 인원
248
연구종류
중재연구
단계/상
해당 없음
상태
대상자모집전
키워드
Borderline hip dysplasia; Arthroscopy; Conservative treatment
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
단일맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Hip arthroscopy
고관절 관절경 검사
The surgical group will undergo standardized hip arthroscopy with capsular management, acetabular rim limited trimming, labral repair, and Cam deformity correction when indicated.
활성 대조군Individualized conservative treatment
Individualized conservative treatment
The conservative treatment protocol includes patient education, NSAIDs for 2-4 weeks, chondroprotective supplementation for 8 weeks, and supervised progressive exercise training for 3 months.
주요결과변수
결과변수측정값 설명시간 범위
The modified Harris Hip Score
The primary outcome was the modified Harris Hip Score (mHHS), assessed at pre-intervention, and at 12 and 24 months post-randomization. It is a clinician-reported instrument designed to evaluate hip function, commonly used to assess functional recovery before and after conservative treatment or hip arthroscopy. The scale encompasses domains such as pain, function, joint range of motion, and deformity, providing a total score ranging from 0 to 100, with higher scores indicating better hip function (typically, 90-100 points represent excellent, 80-89 good, 70-79 fair, and \<70 poor). The instrument has been validated in a relevant population for this trial, with a minimum clinically important difference of 9 points and a patient-acceptable symptom state threshold of 78 points.
Pre-intervention, and at 12 and 24 months post-randomization
이차결과변수
결과변수측정값 설명시간 범위
Visual Analogue Scale
The pain Visual Analogue Scale (VAS) score is a patient-reported instrument designed to quantify pain intensity. It uses a 100-mm line anchored by "no pain" and "worst imaginable pain," with a total score ranging from 0 to 100, where higher scores indicate more severe pain. This instrument has been validated in a relevant population for this trial.
Pre-intervention, and at 12 and 24 months post-randomization
International Hip Outcome Tool-12
The iHOT-12 (international Hip Outcome Tool-12) score is a patient-reported instrument designed to assess hip-related quality of life. Derived from the full iHOT-33 scale, this 12-item instrument covers domains such as symptoms, functional limitations, sports and recreational activities, and work-related concerns. It provides a total score ranging from 0 to 100, with higher scores indicating better hip function and quality of life.
Pre-intervention, and at 12 and 24 months post-randomization
General health: Short Form questionnaire-12 items
The 12-Item Short Form Survey (SF-12) is a validated and widely used health-related quality of life measure, commonly applied to assess hip conditions and treatment outcomes. The SF-12 generates the physical and mental component summary scores originally derived from the 36-Item Short Form Survey (SF-36) with considerable accuracy, while significantly reducing respondent burden. This 12-item scale comprises two dimensions: positive mental state and psychological distress symptoms. Scores from all items are summed to obtain a total score, with higher scores indicating more severe psychological distress.
Pre-intervention, and at 12 and 24 months post-randomization
Patient satisfaction
Patient satisfaction was measured using questions that our team had used in previous trials involving patients undergoing hip arthroscopy for BDDH. During follow-up, we assessed satisfaction in all participants by asking: "Overall, how satisfied are you with the treatment you received?" Responses were rated on a scale from 1 to 10, where 1 indicated dissatisfied and 10 indicated very satisfied.
12 and 24 months post-randomization
Clinical assessment
Clinical assessment performed at baseline and follow up visits consisted of range of passive hip movement, measured using a goniometer, and recording whether a participant experienced pain on each movement. Impingement tests determined whether a participant experienced pain on hip flexion, adduction, and internal rotation (FADIR) or flexion, abduction, and external rotation (FABER).
Pre-intervention, and at 12 and 24 months post-randomization
Adverse events
We recorded the number and type of adverse events up to 24 months. Any adverse events were recorded on the appropriate case report forms and returned to the clinical trial unit, where the chief investigator determined causality and expectedness. Serious adverse events deemed unexpected and related to the trial were reported to the Research Ethics Committee within 10 days.
post-randomization
참여 도우미
적격성 기준

연령대
성인
최소 연령
18 Years
참여 가능한 성별
전체
  1. Age 18-42 years (studies have reported age ≥42 years as a risk factor for hip arthroscopy in BDDH: HR=11.6, 95% CI: 2.5-53.9), either sex;
  2. Symptoms (anterior-lateral groin, lateral, or posterolateral hip pain or discomfort), physical examination findings (limp, clicking, locking, and limited range of motion), and imaging findings consistent with BDDH diagnosis (standing anteroposterior pelvic radiograph with Wiberg lateral center-edge angle \[LCEA\] 18-25°);
  3. Surgeon's assessment that the patient with BDDH will benefit from hip arthroscopy or conservative treatment;
  4. Full understanding of trial benefits and risks, willingness to participate in the intervention and complete follow-up, and signed informed consent.

  1. Standing anteroposterior pelvic radiograph showing Tönnis grade ≥2 and/or joint space <2 mm;
  2. Standing anteroposterior pelvic radiograph showing FEAR index >5°;
  3. Positive physical examination for joint instability: anterior apprehension test (HEER test), abduction-extension-external rotation test in lateral decubitus position (AB-HEER test), or prone external rotation test;
  4. History of high-energy hip trauma, previous ipsilateral or contralateral hip surgery, avascular necrosis of the femoral head, slipped capital femoral epiphysis, Perthes disease, severe osteoporosis, tumor, acetabular stress fracture, or hypertrophic or inflammatory hip disease;
  5. Concomitant consciousness disorder, psychiatric illness, or neuromuscular dysfunction affecting lower limb function;
  6. Contraindications to hip arthroscopy (such as systemic or local infection).
ChunBao Li logoChunBao Li
연구 책임자
ChunBao Li, 의뢰자-연구자, Director of the Department of Sports Medicine, Chinese PLA General Hospital
연락처 정보가 없습니다.